FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 346:420-427 February 7, 2002 Number 6 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background The prognosis of children with high-grade gliomas is uncertain, even when clinical and histologic findings are considered. We investigated whether mutations in the TP53 gene or the degree of expression of p53 protein in high-grade gliomas is associated with progression-free survival in children with these tumors.

Methods Paraffin-embedded specimens of malignant gliomas from children treated in the Children's Cancer Group study CCG-945 were assessed by mutational analysis of TP53 (121 specimens) and immunohistochemical analysis of p53 (115 specimens). For mutational studies, areas of tissue that contained malignant glioma were isolated by microdissection, and the DNA was subjected to polymerase-chain-reaction–based amplification and sequencing of TP53 exons 5, 6, 7, and 8. Immunohistochemical analysis was performed with the use of a microwave-enhanced antigen retrieval and an antibody that bound both wild-type and mutant p53.

Results We found a significant association between overexpression of p53 and outcome; this association was independent of histologic features, age, sex, the extent of resection, and tumor location. The rate (±SE) of progression-free survival at five years was 44±6 percent in the group of 74 patients whose tumors had low levels of expression of p53 and 17±6 percent in the group of 41 patients whose tumors had overexpression of p53 (P<0.001). A nonsignificant association was observed between mutations in TP53 and outcome.

Conclusions Overexpression of p53 in malignant gliomas during childhood is strongly associated with an adverse outcome, independently of clinical prognostic factors and histologic findings.

Source Information

From the Departments of Neurosurgery (I.F.P.) and Pathology (S.D.F., J.W., J.B., R.L.H.), University of Pittsburgh Medical Center and Children's Hospital of Pittsburgh, Pittsburgh; the Children's Oncology Group, Arcadia, Calif. (E.J.H.); the Department of Pathology, Ohio State University, Columbus (A.J.Y.); the Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tenn. (J.M.B.); the Department of Pediatrics, New York University Medical Center, New York (J.L.F.); and the Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles (R.S.).

Address reprint requests to Dr. Pollack at the Department of Neurosurgery, Children's Hospital of Pittsburgh, 3705 Fifth Ave., Pittsburgh, PA 15213, or at pollaci{at}chplink.chp.edu.

Full Text of this Article

This article has been cited by other articles:

• Thorarinsdottir, H. K., Santi, M., McCarter, R., Rushing, E. J., Cornelison, R., Jales, A., MacDonald, T. J. (2008). Protein Expression of Platelet-Derived Growth Factor Receptor Correlates with Malignant Histology and PTEN with Survival in Childhood Gliomas. Clin. Cancer Res. 14: 3386-3394 [Abstract] [Full Text]  
• Warren, K. E. (2008). Pediatric High-grade Gliomas. Am Soc Clin Oncol Ed Book 2008: 472-477 [Abstract] [Full Text]  
• Haque, T., Faury, D., Albrecht, S., Lopez-Aguilar, E., Hauser, P., Garami, M., Hanzely, Z., Bognar, L., Del Maestro, R. F., Atkinson, J., Nantel, A., Jabado, N. (2007). Gene Expression Profiling from Formalin-Fixed Paraffin-Embedded Tumors of Pediatric Glioblastoma. Clin. Cancer Res. 13: 6284-6292 [Abstract] [Full Text]  
• Faury, D., Nantel, A., Dunn, S. E., Guiot, M.-C., Haque, T., Hauser, P., Garami, M., Bognar, L., Hanzely, Z., Liberski, P. P., Lopez-Aguilar, E., Valera, E. T., Tone, L. G., Carret, A.-S., Del Maestro, R. F., Gleave, M., Montes, J.-L., Pietsch, T., Albrecht, S., Jabado, N. (2007). Molecular Profiling Identifies Prognostic Subgroups of Pediatric Glioblastoma and Shows Increased YB-1 Expression in Tumors. JCO 25: 1196-1208 [Abstract] [Full Text]  
• Broniscer, A., Baker, S. J., West, A. N., Fraser, M. M., Proko, E., Kocak, M., Dalton, J., Zambetti, G. P., Ellison, D. W., Kun, L. E., Gajjar, A., Gilbertson, R. J., Fuller, C. E. (2007). Clinical and Molecular Characteristics of Malignant Transformation of Low-Grade Glioma in Children. JCO 25: 682-689 [Abstract] [Full Text]  
• Pollack, I. F., Hamilton, R. L., Sobol, R. W., Burnham, J., Yates, A. J., Holmes, E. J., Zhou, T., Finlay, J. L. (2006). O6-Methylguanine-DNA Methyltransferase Expression Strongly Correlates With Outcome in Childhood Malignant Gliomas: Results From the CCG-945 Cohort. JCO 24: 3431-3437 [Abstract] [Full Text]  
• Lang, F. F., Gilbert, M. R. (2006). Diffusely Infiltrative Low-Grade Gliomas in Adults. JCO 24: 1236-1245 [Abstract] [Full Text]  
• Massimino, M., Gandola, L., Luksch, R., Spreafico, F., Riva, D., Solero, C., Giangaspero, F., Locatelli, F., Podda, M., Bozzi, F., Pignoli, E., Collini, P., Cefalo, G., Zecca, M., Casanova, M., Ferrari, A., Terenziani, M., Meazza, C., Polastri, D., Scaramuzza, D., Ravagnani, F., Fossati-Bellani, F. (2005). Sequential chemotherapy, high-dose thiotepa, circulating progenitor cell rescue, and radiotherapy for childhood high-grade glioma. Neuro Oncol 7: 41-48 [Abstract]  
• Heimberger, A. B., McGary, E. C., Suki, D., Ruiz, M., Wang, H., Fuller, G. N., Bar-Eli, M. (2005). Loss of the AP-2{alpha} Transcription Factor Is Associated with the Grade of Human Gliomas. Clin. Cancer Res. 11: 267-272 [Abstract] [Full Text]  
• Ray, A., Ho, M., Ma, J., Parkes, R. K., Mainprize, T. G., Ueda, S., McLaughlin, J., Bouffet, E., Rutka, J. T., Hawkins, C. E. (2004). A Clinicobiological Model Predicting Survival in Medulloblastoma. Clin. Cancer Res. 10: 7613-7620 [Abstract] [Full Text]  
• Leuraud, P., Taillandier, L., Medioni, J., Aguirre-Cruz, L., Criniere, E., Marie, Y., Kujas, M., Golmard, J.-L., Duprez, A., Delattre, J.-Y., Sanson, M., Poupon, M.-F. (2004). Distinct Responses of Xenografted Gliomas to Different Alkylating Agents Are Related to Histology and Genetic Alterations. Cancer Res. 64: 4648-4653 [Abstract] [Full Text]  
• Broniscer, A., Gajjar, A. (2004). Supratentorial High-Grade Astrocytoma and Diffuse Brainstem Glioma: Two Challenges for the Pediatric Oncologist. The Oncologist 9: 197-206 [Abstract] [Full Text]  
• Allal, A. S., Waelchli, L., Brundler, M.-A. (2003). Prognostic Value of Apoptosis-Regulating Protein Expression in Anal Squamous Cell Carcinoma. Clin. Cancer Res. 9: 6489-6496 [Abstract] [Full Text]  
• Vieyra, D., Senger, D. L., Toyam, T., Muzik, H., Brasher, P. M. A., Johnston, R. N., Riabowol, K., Forsyth, P. A. (2003). Altered Subcellular Localization and Low Frequency of Mutations of ING1 in Human Brain Tumors. Clin. Cancer Res. 9: 5952-5961 [Abstract] [Full Text]  
• Gilbertson, R. J., Hill, D. A., Hernan, R., Kocak, M., Geyer, R., Olson, J., Gajjar, A., Rush, L., Hamilton, R. L., Finkelstein, S. D., Pollack, I. F. (2003). ERBB1 Is Amplified and Overexpressed in High-grade Diffusely Infiltrative Pediatric Brain Stem Glioma. Clin. Cancer Res. 9: 3620-3624 [Abstract] [Full Text]  
• Pollack, I. F., Boyett, J. M., Yates, A. J., Burger, P. C., Gilles, F. H., Davis, R. L., Finlay, J. L., for the Children's Cancer Group, (2003). The influence of central review on outcome associations in childhood malignant gliomas: Results from the CCG-945 experience. Neuro Oncol 5: 197-207 [Abstract]  
• Lang, F. F., Bruner, J. M., Fuller, G. N., Aldape, K., Prados, M. D., Chang, S., Berger, M. S., McDermott, M. W., Kunwar, S. M., Junck, L. R., Chandler, W., Zwiebel, J. A., Kaplan, R. S., Yung, W.K. A. (2003). Phase I Trial of Adenovirus-Mediated p53 Gene Therapy for Recurrent Glioma: Biological and Clinical Results. JCO 21: 2508-2518 [Abstract] [Full Text]  
• O'Neill, B. P., Blondal, H., Yang, P., Olafsdottir, G. H., Sigvaldason, H., Jenkins, R. B., Kimmel, D. W., Scheithauer, B. W., Rocca, W. A., Bjornsson, J., Tulinius, H. (2002). Risk of Cancer among Relatives of Patients with Glioma. Cancer Epidemiol. Biomarkers Prev. 11: 921-924 [Abstract] [Full Text]